The survey shows the evolving landscape of nAMD and DME treatments, highlighting physician preferences, payer influences, and ...

The website you are visiting is protected and accelerated by Imperva. Your computer may have been infected by malware and ...

Sanofi and Regeneron, AstraZeneca, Roche’s Genentech and GSK have provided support for the Living Well with COPD educational ...

Genentech CEO Alexander Hardy, in an interview with STAT, explained that in the world that existed prior to the Inflation Reduction Act’s passage last year, ...

Genentech has been developing medicines to redefine treatment in oncology for more than 35 years, and today, realizing the full potential of cancer immunotherapy is a major area of focus.

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today the Phase III STARGLO study met its primary endpoint of overall s.

Genentech will close its cancer immunology research department, and unit head and renowned cell biologist Ira Mellman, who has been with the company for 17 years, will depart in the coming months.

Jonathan Wosen is STAT’s West Coast biotech & life sciences reporter. You can reach Jonathan on Signal at jwosen.27. For decades, the biotech company Genentech has carved out a reputation in the ...

SOUTH SAN FRANCISCO, Calif., January 28, 2025--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today positive topline results from the overall survival (OS) analysis ...

Genentech, where Stanford President Marc Tessier-Lavigne once served as chief scientific officer, confirmed on Thursday that there were concerns about Alzheimer’s research Tessier-Lavigne co ...